Alkermes plc.·4

Feb 20, 4:22 PM ET

Hopkinson Craig C. 4

4 · Alkermes plc. · Filed Feb 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Alkermes (ALKS) CMO Craig Hopkinson Exercises RSUs, Sells Shares

What Happened

  • Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes (ALKS), converted/ exercised restricted stock units (derivative conversions) into 16,570 ordinary shares across Feb 18–19, 2026. To cover tax withholding obligations he surrendered/disposed of 6,911 shares (3,504 on 2/18 at $32.02, value $112,198; 3,407 on 2/19 at $32.00, value $109,024), for total withholding of $221,222. Net shares added to his position (after withholding) = 9,659 shares. These were routine conversions/withholdings, not open-market purchases or discretionary sales.

Key Details

  • Dates and actions:
    • 2026-02-18: Converted 8,897 RSUs to shares; 3,504 shares withheld for taxes at $32.02 (dispose, $112,198).
    • 2026-02-19: Converted 7,673 RSUs to shares; 3,407 shares withheld for taxes at $32.00 (dispose, $109,024).
  • Gross shares converted: 16,570; shares withheld/disposed for taxes: 6,911; net shares retained: 9,659.
  • Shares owned after transaction: Not specified in this filing.
  • Footnotes of note:
    • F1: Each restricted stock unit (RSU) equals one ordinary share.
    • F2: One award is fully vested per filing language.
    • F3: Another award vests in four equal annual installments commencing 2/19/2026.
  • Filing timeliness: Form 4 was filed 2026-02-20 for transactions on 2/18–2/19 — appears timely (filed within SEC 2-business-day window).

Context

  • These transactions reflect RSU conversions with shares withheld to satisfy tax obligations (a common, routine administrative step), not an open-market sale intended as a liquidity event. For derivative/RSU transactions, conversion + withholding is effectively a cashless settlement to cover taxes; it shouldn't be interpreted alone as a bullish or bearish signal.

Insider Transaction Report

Form 4
Period: 2026-02-18
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    [F1]
    2026-02-18+8,89784,535 total
  • Tax Payment

    Ordinary Shares

    2026-02-18$32.02/sh3,504$112,19881,031 total
  • Exercise/Conversion

    Ordinary Shares

    [F1]
    2026-02-19+7,67388,704 total
  • Tax Payment

    Ordinary Shares

    2026-02-19$32.00/sh3,407$109,02485,297 total
  • Exercise/Conversion

    Restricted Stock Unit Award

    [F1][F2]
    2026-02-188,8970 total
    Ordinary Shares (8,897 underlying)
  • Exercise/Conversion

    Restricted Stock Unit Award

    [F1][F3]
    2026-02-197,67323,019 total
    Ordinary Shares (7,673 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one ordinary share.
  • [F2]This award is fully vested in accordance with its terms.
  • [F3]Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026.
Signature
/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson|2026-02-20

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT